Sigma-Aldrich Signs Agreement With Highlands Stable Isotope Corp. to Supply the Next Generation of Labeled Synthons
ST. LOUIS, April 7 /PRNewswire-FirstCall/ — Sigma-AldrichÂ® (Nasdaq: SIAL) announced today that it has signed an agreement with New Mexico Highlands University through its licensee, Highlands Stable Isotope Corp. (HSI), to exclusively distribute a novel set of patented stable isotope labeled synthetic reagents (www.sigma-aldrich.com/sinext). Under the terms of the agreement, HSI, a leader in the synthesis of amino acids, natural products, monomers for the materials science industry and heterocyclic chemistry, will initially offer approximately 16 compounds in all isotopic combinations through Sigma-Aldrich. In total, HSI’s portfolio currently includes more than 75 newly patented isotopically labeled synthons for the research community, and after the initial offering Sigma-Aldrich expects to distribute all of these materials through its ISOTECÂ® Stable Isotopes product line.
“Sigma-Aldrich is a leader in manufacturing and providing stable isotope products including synthetic building blocks. A partnership with HSI will enable Sigma-Aldrich to provide several new classes of stable isotope reagents,” said Dr. C.T. Tan, ISOTEC Stable Isotope’s R&D Manager at Sigma-Aldrich. “We believe these reagents will improve the speed and quality of the synthesis of stable isotope compounds. The application of these new reagents will help us speed up the drug discovery process, especially for heavyweight deuterated drug discovery.”
Diane Szydel, general manager of ISOTEC Stable Isotopes at Sigma-Aldrich, added, “We are excited about our agreement with HSI. By being the exclusive provider of these patented and novel compounds, we not only expand our comprehensive stable isotope product offering, but believe we will also be able to better serve our customers’ research needs.”
Dr. Rodolfo Martinez, lead scientist for HSI and principal author of this next generation of patented, labeled synthons, said: “We are pleased to collaborate with Sigma-Aldrich. Researchers can be assured that the quality to which they are accustomed will also be represented in all HSI products.”
Dr. Martinez served as a staff member at the National Stable Isotope Resource, Los Alamos National Laboratory, where he began his work in the development of these new stable isotope labeled precursors.
The foregoing release contains forward-looking statements that can be identified by terminology such as “help accelerate drug discovery process,” “will improve the speed and quality,” “better service,” “be assured” or similar expressions, or by express or implied discussions regarding the ISOTEC products, or regarding potential future revenues from information derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that information derived from the ISOTEC products will continue to meet the demands of the marketplace. Nor can there be any guarantee that the ISOTEC products will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding these ISOTEC products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.
About Highlands Stable Isotopes: Highlands Stable Isotopes (HSI) is a new company that focuses its efforts on the development of new isotopically labeled precursors. These new precursors allow for the facile assembly of any compound. HSI specializes in the synthesis of compounds that can be specifically tailored for your research needs. For example, through the use of these new synthons, chiral L-valine, — with chiral differentiation at the methyl groups (13CH2D and 13CD2H) is easily produced. A variety of isotopically tailored natural products have been produced using HSI synthons. HSI is also in the business of providing custom synthesis services to the pharmaceutical, biotechnology and chemical industries as well as to government laboratories. This includes both the regio- and stereo- specific labeling of chiral compounds as well as the differentiation of prochiral centers with deuterium or carbon-13.
Sigma-Aldrich and ISOTEC are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.